Tag: Brent Saunders

November 25, 2018

What is In-licensing?

In-licensing may be pharma’s preferred mode of business development these days. Should that impact your investment strategy?
March 27, 2017

What Are Inversion Deals?

Since losing the fight for healthcare reform, Trump's administration has lost some momentum from companies and the market. It is...
January 30, 2017

Biotech Executives on Trump’s Immigration Ban

Donald Trump's immigration ban has sparked outrage around the world, and biotech executives are speaking out.
December 26, 2016

Top Pharmaceutical News Stories of 2016

2016 saw countless pharmaceutical companies taken to task for price gouging. Close to the end of the year, a related...
December 20, 2016

Allergan to Acquire Acelity L.P. Inc.'s LifeCell Corporation for $2.9 Billion

Allergan, a leading global biopharmaceutical company, and Acelity today announced that they have entered into a definitive agreement under which...
October 4, 2016

Another Acquisition for Allergan Makes Six Since August

Six acquisitions indicate Allergan’s refined strategic focus, as well as CEO Brent Saunders’ continued commitment to a “growth pharma” business...
September 20, 2016

Allergan to Acquire Tobira Therapeutics

Allergan (NYSE:AGN) and Tobira Therapeutics, Inc. (NASDAQ: TBRA) announced that they have entered into a definitive agreement.